RxDoctor Payments DataLook up a doctor →

Seth Page, MD

Hematology & Oncology · Wichita, KSNPI 1518974948

Payments from drug & device makers

$19,120in general payments, 2019–2025

Across 1,065 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Merck$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$1K
  • Rigel Pharmaceuticals, Inc.$1K
  • AstraZeneca$857
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$5003%
  • Speaking & faculty fees$8505%
  • Food & beverage$15,71186%
  • Education$3472%
  • Other$7814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis83$1,652
Merck48$1,580
E.r. Squibb & Sons, L.L.C.115$1,387
Pfizer117$1,323
Rigel Pharmaceuticals, Inc.11$1,023
AstraZeneca(2 entities)45$857
Amgen55$843
Bristol Myers Squibb41$583
Astellas Pharma US Inc29$553
Verity Pharmaceuticals Inc.1$500
Johnson & Johnson(2 entities)29$469
AbbVie28$443
Array Biopharma Inc33$409
Daiichi Sankyo Inc.22$402
Genentech USA, Inc.22$376
EMD Serono, Inc.24$371
Sanofi18$353
Seagen Inc.21$320
GSK19$319
Gilead(2 entities)22$289
Takeda Pharmaceuticals U.S.A., Inc.12$287
Pharmacyclics LLC, An Abbvie Company16$270
Eisai Inc.16$269
Dova Pharmaceuticals9$236
Lilly USA, LLC14$234
Tersera Therapeutics LLC11$232
Ipsen Biopharmaceuticals, Inc11$193
Epizyme, Inc.13$192
Incyte Corporation11$187
Sun Pharmaceutical Industries Inc.10$175
Taiho Oncology, Inc.9$153
Jazz Pharmaceuticals Inc.7$151
Regeneron Healthcare Solutions, Inc.8$145
Exelixis Inc.9$140
Beigene USA, Inc.9$133
Karyopharm Therapeutics Inc.6$131
Bayer8$131
AVEO Pharmaceuticals, Inc.6$130
Blueprint Medicines Corporation8$120
Puma Biotechnology, Inc.8$110
Boehringer Ingelheim5$108
Deciphera Pharmaceuticals Inc.2$105
Foundation Medicine, Inc.5$97
Servier Pharmaceuticals LLC5$87
Stemline Therapeutics Inc.4$67
Agios Pharmaceuticals, Inc.4$65
Acrotech Biopharma Inc.4$58
Clovis Oncology, Inc.4$58
Aurobindo Pharma USA, Inc.4$56
Springworks Therapeutics, Inc.3$52
Blue Earth Diagnostics3$52
CTI Biopharma Corp.3$46
Alnylam Pharmaceuticals Inc.3$46
Dendreon Pharmaceuticals LLC2$44
TG Therapeutics, Inc.2$43
AMAG Pharmaceuticals, Inc.3$37
Geron Corporation2$37
Sobi, Inc2$36
Morphosys, US Inc.2$36
ADC Therapeutics America, Inc.2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,120 in reported general payments places this provider in the 55th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$4,165,315
Medicare patients
1,105
Services billed
151,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide27$525,822
CabometyxCabozantinib S-Malate21$508,825
VenclextaVenetoclax40$307,922
CalquenceAcalabrutinib Maleate17$186,849
BrukinsaZanubrutinib13$171,162
Abiraterone Acetate13$58,951
Imatinib Mesylate23$17,708
XareltoRivaroxaban17$16,519
EliquisApixaban24$16,510
Letrozole341$5,256
Oxycodone Hcl27$2,506
Ondansetron Hcl57$1,635
Dexamethasone36$1,424
Megestrol Acetate16$1,420
Gabapentin59$1,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$140$508,82521 claims
AbbVieVenclexta$443$307,92240 claims
AstraZenecaCalquence$857$186,84917 claims
Beigene USA, Inc.Brukinsa$133$171,16213 claims
Johnson & JohnsonXarelto$469$16,51917 claims
PfizerEliquis$1,323$16,51024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 97 hematology & oncology providers in Kansas.

Other hematology & oncology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →